SCHEMBL3870882

SCHEMBL3870882

CCOC(=O)CC[C@H](NC(=O)CN)C(=O)OCC

nearest known ligand 0.79

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.79
KMT2A Q03164 2/20 0.74
POLB P06746 1/20 0.74
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
HPGD P15428 1/20 0.51
HSD17B10 Q99714 1/20 0.51
NOD1 Q9Y239 3/20 0.45
CYP1A2 P05177 2/20 0.44
CAD P27708 1/20 0.41
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
GAA P10253 2/20 0.39
MGAM O43451 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
NOD2 Q9HC29 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4629331 1.00 L3MBTL1 (0.79) L3MBTL1KMT2APOLBKDM4EALDH1A1
SCHEMBL22111187 1.00 L3MBTL1 (0.79) L3MBTL1KMT2APOLBKDM4EALDH1A1
SCHEMBL30531893 0.89 L3MBTL1 (0.62) L3MBTL1KMT2APOLBKDM4EALDH1A1
SCHEMBL15730803 0.88 L3MBTL1 (1.00) L3MBTL1KMT2APOLBKDM4EALDH1A1
SCHEMBL4629356 0.87 L3MBTL1 (0.59) L3MBTL1KMT2APOLBKDM4EALDH1A1
SCHEMBL4629355 0.87 L3MBTL1 (0.59) L3MBTL1KMT2APOLBKDM4EALDH1A1
SCHEMBL31228993 0.87 L3MBTL1 (0.60) L3MBTL1KMT2APOLBKDM4EALDH1A1
SCHEMBL4189292 0.87 L3MBTL1 (0.84) L3MBTL1KMT2APOLBKDM4EALDH1A1
SCHEMBL4189297 0.87 L3MBTL1 (0.84) L3MBTL1KMT2APOLBKDM4EALDH1A1
SCHEMBL30531875 0.86 L3MBTL1 (0.59) L3MBTL1KMT2APOLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598318-B2 reacting poly(ethylene glycol) or its sodium salt and the poly(dichlorophosphazene), reacting the product formed with an oligopeptideester or its acid salt EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) 2009-10-06 US disclosed
EP-1618117-B1 TUMOR SELECTIVE AND BIODEGRADABLE POLYPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTITUMOR AGENT, AND PREPARATION METHOD THEREOF TRUSTEES EWHA WOMANS UNIVERSIT (KR) 2008-04-23 EP disclosed
EP-1618117-A4 TUMOR SELECTIVE AND BIODEGRADABLE POLYPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTITUMOR AGENT, AND PREPARATION METHOD THEREOF TRUSTEES EWHA WOMANS UNIVERSIT (KR) 2007-04-11 EP disclosed
WO-2006033523-A1 THERMOSENSITIVE AND BIOCOMPATIBLE AMPHIPHILIC POLY(ORGANOPHOSPHAZENES) AND PREPARATION METHOD THEREOF EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) 2006-03-30 WO disclosed
US-20060063910-A1 Thermosensitive and biocompatible amphiphilic poly(organophosphazenes) and preparation method thereof EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) 2006-03-23 US disclosed
EP-1618117-A1 TUMOR SELECTIVE AND BIODEGRADABLE POLYPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTITUMOR AGENT, AND PREPARATION METHOD THEREOF Board of Trustees, Ewha Womans University (KR) 2006-01-25 EP disclosed
US-6951953-B2 Tumor selective and biodegradable polyphosphazene-platinum(II) conjugate antitumor agent, and preparation method thereof EWHA WOMANS UNIVERSITY (KR) 2005-10-04 US disclosed
WO-2004096820-A1 TUMOR SELECTIVE AND BIODEGRADABLE POLYPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTITUMOR AGENT, AND PREPARATION METHOD THEREOF BOARD OF TRUSTEES, EWHA WOMANS UNIVERSITY (KR) 2004-11-11 WO disclosed
US-20040219127-A1 Tumor selective and biodegradable polyphosphazene-platinum(II) conjugate antitumor agent, and preparation method thereof EWHA WOMANS UNIVERSITY (KR) 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040219127-A1 Tumor selective and biodegradable polyphosphazene-platinum(II) conjugate antitumor agent, and preparation method thereof PHOSPHO1, FOLR1, PCNA L3MBTL1 1674/4885KMT2A 1444/4885POLB 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.